A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

NCT03344367 Phase 1 UNKNOWN

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult subjects with relapsed and refractory B-cell Non-Hodgkin lymphoma.

Details

Lead sponsor	Peking University
Phase	Phase 1
Status	UNKNOWN
Enrolment	20
Start date	2017-11-16
Completion	2022-03

Conditions

• Non Hodgkin Lymphoma

Interventions

• JWCAR029

Primary outcomes

• Treatment-related adverse events (AEs) — 2 years
  Physiological parameter
• Dose-limiting toxicities of JWCAR029 — 28 days after JWCAR029 infusion
  Physiological parameter
• Objective response rate (ORR) — 2 years
  Lugano criteria

Countries

China